In recent years, China has systematically enhanced its policy framework for innovative pharmaceuticals and medical devices and established a comprehensive, full-cycle support mechanism encompassing research and development, regulatory approval, manufacturing, reimbursement, and clinical application. This integrated approach has markedly accelerated the review-approval process and market entry of innovative medical products. Key regions including Beijing, Shanghai and the Guangdong-Hong Kong-Macao Greater Bay Area have demonstrated significant achievements through initiatives such as optimized clinical trial protocols, expedited regulatory pathways, and diversified payment models. Nevertheless, challenges persist, including restrictive performance metrics in hospital, underdeveloped multi-payer reimbursement systems, and interdepartmental coordination gaps. Moving forward, sustained efforts in policy harmonization, reimbursement mechanism innovation, core technology breakthroughs, and global collaboration should be critical to advancing the high-quality development of Chinese innovative pharmaceuticals and devices.

Objective:To determine the effect of Chuju total flavonoids (CJTF) on the secreted frizzled-related protein 4 (SFRP4) expression in Wnt pathway in rheumatoid arthritis (AR) model rats. Methods:hTe role of CJTF in the treatment of AR model rats was evaluated by rat arthritis score and paw edema score. The expression regulation of the SFRP4,β-catenin and C-myc in Wnt pathway in AR model rats was detected by RT-PCR and Western blot atfer CJTF gavage treatment. Results:Atfer CJTF treatment, the rat arthritis score and paw edema score in AR model rats were signiifcantly decreased when the AR model rats were treated with CJTF, the SFRP4 expression was signiifcantly up-regulated, while theβ-catenin and C-myc gene expression were signiifcantly down-regulated in AR model rat synovial tissues. Conclusion:CJTF has significant therapeutic effect and inhibitory effect on Wnt pathway activation by targeting SFRP4 in AR model rat synovium.

In order to probe into the role of plasma glucagon in the pathogenesis of NIDDM, the concentrations of fasting blood glucose, serum insulin and plasma glucagon were assayed in 327 subjects with normal glucose tolerance (group Ⅰ), 25 patients with NIDDM (group Ⅱ) and 20 NIDDM patients treated with drugs (group Ⅲ). The levels of blood glucose, plasma glucagon and serum insulin in group Ⅱ were 9. 28?2.30 mmol/L,159. 55?34. 13ng/L and 15. 16?10. 79mIU/L respectively, and were significantly higher than those of group Ⅰ(4. 71?0. 64mmol/L,83.12?12.39ng/L and 10. 43?6. 86mIU/L respectively). The levels of blood glucose and plasma glucagon in group Ⅲ were 7. 15?2. 44 mmol/L and 124. 99?37. 23 ng/L respectively and were lower than those of group Ⅱ, no significant difference in serum insulin levels was noted. Correlation analysis showed that blood glucose had a positive linear correlation with plasma glucagon in the three groups (r=0. 8720,0. 9400,0. 8731,respectively, P